Latest Research News from the Foundation for Women's Cancer and Society of Gynecologic Oncology

Article

An update from the Foundation for Women's Cancer and Society of Gynecologic Oncology

Hear from Dr. Anil Sood, Foundation for Women's Cancer Research Chairman, and Carol Brown, 2014 Society of Gynecologic Oncology Program Chair, about research of interest to women and the public presented at the 2014 SGO Annual Meeting on Women's Cancer. (https://www.youtube.com/watch?v=KKB63TGlOcQ&feature=youtu.be)

Recent Videos
Ann H. Partridge, MD, MPH, in an interview with Oncology Nursing News at 2024 ESMO Congress.
Elizabeth Burton in an interview with Oncology Nursing News
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
magnifying glass looking at DNA

Elacestrant Proves Effective in Advanced, Co-Mutated Breast Cancer

Brielle Benyon
October 24th 2024
Article

Advanced practice providers discuss the second-line use of elacestrant in patients with co-mutated, ER+, HER2—advanced or metastatic breast cancer

The Vitals

What New Cancer Drugs Were Approved in 2023?

Lindsay Fischer
January 1st 2024
Podcast

In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.

RX pill bottle

FDA Delays Decision Dates for Sotorasib and Obeticholic Acid

Ariana Pelosci
October 23rd 2024
Article

The PDUFA dates have been pushed for sotorasib and obeticholic acid for metastatic colorectal cancer and primary biliary cholangitis, respectively.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Lindsay Fischer
December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

lymphoma cell

Nivolumab Regimen Boosts Outcomes in Advanced Hodgkin Lymphoma

Russ Conroy
October 22nd 2024
Article

Nivolumab plus AVD outperformed brentuximab vedotin plus AVD in patients with advanced-stage classical Hodgkin lymphoma.

liver

FDA OKs NDA Resubmission of Rivoceranib Plus Camrelizumab for HCC

Ryan Scott
October 22nd 2024
Article

The FDA accepted a resubmission of a new drug application for frontline rivoceranib plus camrelizumab to treat unresectable, metastatic HCC.

© 2024 MJH Life Sciences

All rights reserved.